Kornimate/medical-research-clean huggingface dataset:
sweden cancerome analysis network - breast (scan-b) coupled to psychological resilience

Conditions: Breast Cancer

Summary: this study aims to define the association between psychological resilience and biomolecular signatures in cancer patients and to relate psychological resilience to prognosis, as this could potentially open up a novel avenue of therapeutic interventions, medical as well as psychosocial.

individual patients differ in psychological response when receiving a cancer diagnosis. given the same disease burden some patients master the situation well and others do experience a great deal of stress, depression and lowered quality of life. a patient's mental resistance after acquiring a threat, like a cancer diagnosis, called psychological resilience, is known to impact the outcome of the disease. patients with high psychological resilience are likely to experience less stress reactions, and a better adaptation and management of the life threat and the demanding therapeutic interventions. how this phenomenon of mastering difficult situations is reflected also in bio-molecular processes is not much studied and how these have an impact on the cancer prognosis and the effectiveness of treatment is today not fully understood. however, there is evidence that expressing the emotions evoked is an important part of fighting cancer. our hypothesis is that patients displaying a high psychological resilience, according to a standardized method "the connor-davidson resilience scale" i.e. low stress reactions, low hopelessness and low fatigue, also present a specific pattern of biomolecular signatures in blood, represented by its epigenome, microrna and proteomic patterns. this project specifically aims to investigate if breast cancer patient´s psychological resilience can be coupled to bio-molecular parameters, using advanced "omics" and as a secondary aim, if it relates to prognosis and quality of life one year after diagnosis.

Eligibility criteria:
inclusion criteria: * newly diagnosed patients with primary breast cancer * patients consented to be included in the scan-b study at (blekinge county hospital, central hospital växjö and hallands hospital halmstad hbg?? * oral and written consent for the scan-b resilience study * age ≥ 18 years * patients that do understand the swedish language (written and spoken) exclusion criteria: * no diagnosis of breast cancer * not consented to be included in the scan-b study * do not understand the swedish language

Keywords: psychological resilience biomarkers molecular fingerprint quality of life (qol) body and mind cd-risc sf-36
2d perfusion dsa for the quantification of infrapopliteal angioplasty

Conditions: Ischemia Limb

Summary: a custom-made, 2d-perfusion digital subtraction angiography (pdsa) algorithm has been designed and implemented towards foot perfusion quantification following endovascular treatment of critical limb ischemia (cli), in order to assist intra-procedural decision-making and enhance clinical outcomes.

this is a prospective, single-center, study investigating the feasibility of 2d-pdsa using newly-developed, non-commercially available, color-coded software for the quantification of foot perfusion following infrapopliteal angioplasty for the treatment of cli. in total, 7 consecutive patients scheduled to undergo infrapopliteal endovascular treatment of cli were enrolled. perfusion blood volume (pbv), mean transit time (mtt), and perfusion blood flow (pbf) maps were extracted by analyzing time-intensity curves and signal intensity on the perfused vessel mask. mean values calculated from user-specified rois on perfusion maps were employed to evaluate the patient's pre- and post- endovascular treatment condition.

Eligibility criteria:
inclusion criteria: * patients prescheduled for infrapopliteal angioplasty due to chronic limb-threatening ischemia. * written informed consent obtained exclusion criteria: * image post-processing not feasible due to significant motion artifacts produced during dsa

Keywords: infrapopliteal angioplasty tissue perfusion quantification
evaluation of adherence of women with fibromyalgia to walking prescriptions

Conditions: Fibromyalgia

Summary: although there are many studies evaluating adherence to supervised walking programs in patients with fibromyalgia (fm), there are limited studies evaluating adherence to unsupervised walking programs.

although there are many studies evaluating adherence to supervised walking programs in patients with fibromyalgia (fm), there are limited studies evaluating adherence to unsupervised walking programs. purposes of this study were (1) to assess whether walking as exercise was prescribed by their physiatrist in turkish women with fm who received pharmacological therapy, (2) to illustrate the frequency of patients who walk regularly as exercise, (3) to clinically compare patients who walk regularly as exercise and those who do not, and (4) to determine factors related to adherence to walking prescriptions.

Eligibility criteria:
inclusion criteria: * be between 18-70 years old * female gender * pharmacological therapy has been recommended in the last 1 year exclusion criteria: * neurological disease or orthopedic problem presence that may be the reason of functional impairment * neurological deficit presence

Keywords: fibromyalgia walking adherence
a trial comparing s1 generic with capecitabine in metastatic breast cancer (mbc)

Conditions: Metastatic Breast Cancer

Summary: comparing s1 generic with capecitabine in patients with metastatic breast cancer.

comparing s1 generic(tegafur，gimeracil and oteracil potassium capsules) with capecitabine in patients with metastatic breast cancer.

Eligibility criteria:
inclusion criteria: * histologically confirmed breast cancer * pretreated metastatic breast cancer not more than 2 lines chemotherapy * have not been previously treated with capecitabine,oral fluracil * ecog performance status of ≤ 1 * be female and ≥ 18 and ≤ 75 years of age * have at least one target lesion according to the recist criteria 1.1 exclusion criteria: * pregnant or lactating women * ecog ≥ 2 * have been treated with capecitabine * evidence of cns metastasis * history of another malignancy within the last five years except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix or a contralateral breast cancer * abnormal laboratory values: hemoglobin \ upper limit of normal (uln), serum bilirubin \> uln, alt and ast \> 5×uln, akp \> 5×uln * serious uncontrolled intercurrent infection * life expectancy of less than 3 months

Keywords: capecitabine tegafur，gimeracil and oteracil potassium capsules
toleromune house dust mite follow on study

Conditions: House Dust Mite Allergy; Rhinoconjunctivitis

Summary: house dust mites (hdm) are arachnids that infest bedding, carpet, upholstered furniture and fabric. like many other allergens, exposure to hdm allergens in sensitised patients is associated with poorer lung function, greater medication requirements and more asthma symptoms as well as chronic rhinosinusitis symptoms. in contrast to other allergens, there is evidence that hdma leads to the development of asthma, in addition to exacerbating pre-existing asthma in hdm-sensitised patients. toleromune hdm is currently being developed for the treatment of hdm allergy. the purpose of this optional observational follow-on study is to evaluate the continued efficacy of tm-hdm in hdm allergic subjects based on change in trss from th002 baseline approximately two years after the completion of the baseline eec visit in th002 following challenge with hdm allergen in an eec.

subjects who completed all dosing visits and the post treatment challenge (ptc) in study th002 will be invited to attend the screening visit for th002a. subjects will attend for 3 visits to the eeu on successive days. following the last eec visit a follow-up visit will be performed 3-10 days later.

Eligibility criteria:
inclusion criteria: * previously randomised in study th002, completed all dosing visits and the ptc exclusion criteria: * "partly controlled" and "uncontrolled" asthma * history of anaphylaxis to house dust mite allergen * fev1 \<80% of predicted. * symptoms of a clinically relevant illness * subjects who cannot tolerate allergen challenge in the eec

Keywords: house dust mite allergy rhinoconjunctivitis environmental exposure unit immunotherapy toleromune hdm
a study of two forms of pentamidine in the treatment of pneumocystis carinii pneumonia (pcp) in patients with aids

Conditions: Pneumonia, Pneumocystis Carinii; HIV Infections

Summary: to compare parenteral versus inhaled pentamidine in patients with documented pneumocystis carinii pneumonia (pcp) with aids.


Eligibility criteria:
exclusion criteria co-existing condition: patients with the following are excluded: * previous history of adverse reaction to pentamidine. * history of asthma. * pulmonary kaposi's sarcoma. patients with the following are excluded: * previous history of adverse reaction to pentamidine. * history of asthma. * pulmonary kaposi's sarcoma. * inability to understand the consent procedure. all patients hospitalized at cedars-sinai medical center with aids and possible pneumocystis carinii pneumonia (pcp) will be eligible. * patients with hiv antibody or aids and a clinical presentation suggesting pcp are eligible.

Keywords: aids-related opportunistic infections pneumonia, pneumocystis carinii pentamidine injections, intravenous administration, inhalation aerosols acquired immunodeficiency syndrome
assessment of tracp-5b in primary and secondary osteoporosis

Conditions: Osteoporosis

Summary: assessment of the tracp-5b level in 1ry op and 2ry op such as ra and seronegative spondylitis, that may help in surrogating the use of bmd.

osteoporosis is a disease characterized by low bone density and a deterioration of bone microarchitecture that reduces bone strength and increases the risk of fracture. the hallmark of osteoporosis is the loss of both bone mineral and bone matrix. although bone mass density (bmd) is still the gold standard for the diagnosis of osteoporosis, but bone turnover markers (btms) can provide helpful information regarding the bone remodelling process. one of these relatively recent markers is the tartrate-resistant acid phosphatase (tracp). tracp, which was first identified in human leukocytes, has 2 isoforms trap-5a derived from macrophages and dendritic cells and tracp-5b secreted by osteoclasts. it is believed that tracp-5b is a useful marker of osteoclast activity, even a marker for osteoclast number, as it is associated with osteoclast differentiation, activation and proliferation. furthermore, it has the advantage of not being affected by renal dysfunction, nor food intake and has a weak diurnal variability. and this is why it has been used as one of the bone turnover markers in evaluating the efficacy of different anti-resorptive treatments in postmenopausal osteoporosis and in 2ry op due to rheumatoid arthritis as well as in evaluating its specificity in identification of postmenopausal op when compared to measurement of more expensive, relatively unavailable bone mineral density (bmd).so far, limited researches are available regarding the tracp-5b level difference among 1ry op (postmenopausal women) and 2ry op (ex. ra, spa).

Eligibility criteria:
inclusion criteria: * patients with 1ry op diagnosed by dxa scan . * any ra and spa patients (older than 18 years old), who fulfill the for mentioned diseases criteria with secondary osteoporosis as diagnosed by dxa scan. exclusion criteria: * patients unwilling to participate in the study. * patients with other autoimmune diseases. * patients depending on glucocorticoids with in the last 6 month. * patients with other causes of 2ry op (ex. endocrinal abnormalities, gastrointestinal diseases, renal diseases.....etc.)

Keywords: primary and secondary
aquablation in benign prostatic hyperplasia in canada

Conditions: Urologic Diseases

Summary: to document the clinical outcome of aquablation therapy for bph patient in canadian cohort.

patients will be followed up for 3 years as standard of care.

Eligibility criteria:
inclusion criteria: * primary diagnosis of benign prostate hypertrophy (bph) * male subjects of ≥ 18 years of age * candidate for aquablation therapy as per clinical decision of investigator * willing and able to accurately complete questionnaires * willing and able to provide signed and dated informed consent exclusion criteria: * characteristics indicating a poor compliance with study protocol requirements. * disease or other health condition that is not suitable for this study. * unable or unwilling to provide signed informed consent.

Keywords: benigh prostate hypertrophy
validation of radioisotope guided lymphadenectomy for loco-regional staging in patients with intermediate or high-risk prostate cancer

Conditions: Patient With Prostate Cancer

Summary: the diagnosis of a ganglionic infringement(achievement) at a patient reached (affected) by a prostate cancer is a factor(mailman) of bad forecast. the locoregional ganglionic staging is a very important element in the coverage (care). he allows to determine the local extension of the disease and the type(chap) of therapeutics to implement(operate) after the surgery. the standard cleaning out at present recommended by the european company (society) of urology at the patients at intermediate or high risk of second offense (recurrence) after local treatment(processing), has to concern the obturating pit, the internal and external iliac territories. however this type(chap) of cleaning out does not seem to solve all the problems of locoregional stratification. indeed, several studies concerning the radio-controlled cleaning out highlighted that 10 in 30% of ganglions.


Eligibility criteria:
inclusion criteria: * subject man, whose age is greater than or equal to 18 years * carrier of cancer intermediate risk non-metastatic prostate or high relapse * subject with an initial balance sheet expansion, regional and general negative by scanner, abdominopelvic mri or bone scan, * subject has undergone a medical examination in connection with the study, * topic for which a radical prostatectomy is considered curative purposes, * supported by subject surgical teams involved in the study, * topic affiliated to a social security scheme, * subject who signed informed consent. exclusion criteria: * subject man, whose age is less than 18 years * subject who have received hormone therapy or radiation therapy for prostate cancer * subject who had surgery for prostate adenoma (transurethral resection or open surgery) because of potential difficulties injection of radioactive tracer in the gland, * subject has a history of pelvic surgery or radiotherapy, * subject with inguinal hernia repair history of laparoscopic, * subject refusing blood transfusions, * subject is not agreeing to participate in this study and did not sign the informed consent.
school readiness intervention for preschool children with sickle cell disease

Conditions: Sickle Cell Disease

Summary: the study participant is being asked to take part in this clinical trial, a type of research study, because the participant is a young child with sickle cell disease or the caregiver of a child with sickle cell disease. this study is being done to test a school readiness program for children with sickle cell disease (ages 3.5-6,5 years old). primary objective assess feasibility and acceptability of an adapted school readiness intervention among preschool children (ages 3.5-6.5) diagnosed with sickle cell disease. secondary objectives objective 1: measure preliminary efficacy of the adapted school readiness intervention compared to routine care among preschool children ages (3.5-6.5) diagnosed with sickle cell disease. objective 2: examine implementation factors (i.e., barriers and facilitators) during post-intervention.

* group randomization- parent and child will be randomly selected (like the flip of a coin) to receive either the school readiness intervention or the standard school resources. * attend virtual classroom program sessions- if the participant is in the school readiness group, the caregiver, will attend about 8 weeks of sessions virtually with a teacher and a caregiver of a child with sickle cell, for a total of 8 sessions. the sessions will be during the summer and done in a group. each session will last about 1 ½ hours and will be video recorded. these sessions will be shared with another researcher for feedback and consistency. * complete a caregiver interview-if you are in the school readiness group, a member of the study team will interview you after the virtual classroom sessions are over. the interview will take about 15-20 minutes and will be audio recorded. the caregiver will be asked for suggestions and how satisfied with the program. * complete assessments - caregiver and child will complete a set of assessments that evaluate school readiness skills (e.g., early math and reading), child behaviors, and parent-child relationships before and after the intervention.

Eligibility criteria:
inclusion criteria * diagnosed with sickle cell disease of any genotype. * enrolled on the institutional protocol: sickle cell clinical research intervention program (sccrip) * age 3.5-6.5 years inclusive at the time of enrollment * english as the primary language * research participant and one parent willing to participate and provide consent/assent according to institutional guidelines caregiver participants * have a child diagnosed with scd of any genotype between the ages of 3.5-6.5 years and enrolled in sccrip * english as the primary language exclusion criteria * do not have a child diagnosed with scd of any genotype between the ages of 3.5-6.5 years and enrolled in sccrip * non-english speakers
a study to evaluate the efficacy and safety of recombinant human growth hormone in children with achondroplasia

Conditions: Achondroplasia

Summary: to evaluate the efficacy and safety of recombinant human growth hormone in children with achondroplasia


Eligibility criteria:
inclusion criteria: * 2-10 years old; * in tanner i stage; * ach, documented and confirmed by genetic testing; * short stature; * ambulatory and able to stand or walk without assistance; * parent(s) or guardian(s) consent； * had never been treated with growth hormone exclusion criteria: * short stature condition other than ach; * evidence of growth plate closure (proximal tibia, distal femur); * had a fracture of the long bones within 6 months prior to screening; * planned or expected bone-related surgery; * chronic diseases condition that affect bone metabolism and weight; * severe intracranial hypertension

Keywords: achondroplasia
oral curcumin administration to remit metabolic syndrome

Conditions: Metabolic Syndrome

Summary: the metabolic syndrome consists of a set of risk factors that increases the probability to develop heart diseases and type 2 diabetes, two of the principal chronic diseases that affect mexican population. the curcumin is a compound that is extracted from the root of a plant called cúrcuma longa. there exists information that curcumin helps to diminish weight and the levels of blood glucose and blood fats. the hypothesis of this study is: that curcumin administration combined with diet and exercise remits the metabolic syndrome.

objective: the aim of this study is to determinate the efficacy of oral administration of curcumin in the remission of metabolic syndrome. design: clinical trial, randomized, double blind, placebo controlled. study population: men and women from 20 to 55 years old with metabolic syndrome according to the atp iii criteria, will be included. study groups: intervention and control group. sample size: it was calculated using a statistical power of 80%, an alpha value of 0.05. a 50% of the difference in the mean of remission of metabolic syndrome between control group and intervention groups was considered. the estimated sample size was 220 subjects for each group. process: all eligible participants according to inclusion and exclusion criteria, will be randomized to one of the study groups. the intervention group will receive a total dose of curcumin 1.2 g / black pepper 10 mg a day; and control group will receive a total dose of hydrolyzed collagen 1.2 g / black pepper 10 mg a day; plus dietary and exercise recommendations for both groups during three months. the blood concentrations of glucose, triglycerides, and hdl cholesterol will be measured, as well as the abdominal perimeter and blood pressure, at baseline conditions, at one month and three months after treatment. statistical analysis: numerical values will be expressed as mean ± standard deviation; categorical variables will be expressed as proportions. differences between the groups were estimated by unpaired student t test for numerical variables (mann-whitney u test for skewed data) or chi-square and fisher´s exact test for categorical variables. intragroup differences were estimated by paired student t-test.

Eligibility criteria:
inclusion criteria: * women and men. * 20 to 55 years old. * diagnosis of metabolic syndrome according to the atp iii criteria. * informed consent of the participant. exclusion criteria: * diabetes or hypoglycaemic therapy. * high blood pressure o anti-hypertensive treatments. * hypertriglyceridemia (\>400 g/dl) or lipid lowering treatment. * neoplasia disease. * thyroid disease * syndrome of polycystic ovary. * pregnancy or lactation. * smoking. * anti-inflammatory medicines in the last two months. * food supplements in the last two months.
multicenter trial evaluating quality of tears produced by nasal neurostimulation

Conditions: Dry Eye Syndromes

Summary: the objectives of this study are: * to compare the change in levels of tear proteins and inflammatory mediators pre and post administration between the intranasal and extranasal applications * to compare the goblet cell count following application between the intranasal and extranasal applications * to compare fluorescein tear clearance with the application of the device intranasally and extranasally applications

in this study, subjects will participate for three study days during up to a 44 day period, consisting of a screening examination to determine eligibility on one day and study applications on two different days. there are two applications, intranasal and extranasal. subjects will receive both applications, in random sequence, one at each of the two application days (visit 2 and visit 3). the two applications consist of: * active intranasal device application * active extranasal device application

Eligibility criteria:
inclusion criteria: * bilateral dry eyes * capable of providing written informed consent exclusion criteria: * chronic or recurring epistaxis (nosebleeds) * blood coagulation disorder * uncontrolled or poorly controlled diabetes * heart or pulmonary disease * females who are pregnant, planning a pregnancy or nursing